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Abstract
Background: Colchicine is the standard treatment for familial Mediterranean fever (FMF), preventing attacks and
inflammatory complications. True resistance is rare and yet not clearly defined. We evaluated physicians’ definition
of colchicine resistance and report how they manage it.
Patients and methods: We recruited patients with a clinical diagnosis of FMF, one exon-10 Mediterranean fever
(MEFV) gene mutation and considered resistant to colchicine, via networks of expert physicians. Clinical, biological
characteristics and information about colchicine treatment (dose adjustment, compliance) were collected. The
severity of FMF was assessed by the Tel Hashomer criteria.
Results: We included 51 patients, most females (55%), mean age 34 ± 23.1 years years (range 4.7–86.3). Overall, 58%
(27/47) patients had homozygous M694 MEFV gene mutations. Seventeen of 42 patients (40%) declared full adherence to
colchicine treatment, greater for children (48%) than adults (22%). Physicians considered colchicine resistance with > 6
attacks/year (n = 21/51, 42%), > 4 attacks in the last 6 months (n= 13/51, 26%), persistent inflammation (n= 23/51, 45%),
renal amyloidosis in (n = 6/28, 22%) of adult patients and intolerance to an increase in colchicine dose (n = 10/51, 19%),
and other reasons (n = 13/51, 23%), including chronic arthralgia (n = 6/51, 12%). Interleukin 1–targeting drugs represented
the only alternative treatments in addition to daily colchicine.
Conclusion: Resistance to colchicine is rare (<10% of patients) and mostly observed in severe MEFV genotypes. The main
reasons for physicians assessing resistance were severe clinical symptoms, persistent subclinical inflammation, and
secondary amyloidosis. Low adherence to colchicine treatment is a key component of resistance.
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Significance and innovations
– In pediatric care setting, the most important
reason to consider resistance to colchicine
treatment in patients with FMF was a high
frequency of attacks.
– In adult care setting, the most important reason to
consider resistance to colchicine treatment was
secondary amyloidosis.
– In both group, digestive intolerance, persistent
subclinical inflammation and joint symptoms
contributed to colchicine resistance.
– Overall full compliance to colchicine treatment
was low (40%), especially in the adult care setting
group (22%)
Background
Familial Mediterranean fever (FMF) is the historical proto-
type of a group of inherited inflammatory disorders of
innate immunity, so-called autoinflammatory diseases. FMF
is essentially observed in Mediterranean populations, affect-
ing more than 100,000 people [1]. The main clinical charac-
teristics are self-limited acute febrile attacks accompanied
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by peritoneum, pleura, skin, muscle and joint inflam-
mation. FMF severely impairs quality of life and causes
secondary inflammatory complications such as amyloid A
amyloidosis [2].
Daily treatment with colchicine was introduced in
1972 to prevent FMF attacks and secondary amyloidosis
by also reducing the level of sub-clinical inflammation
[2]. The action mechanisms of colchicine are diverse and
still unclear, but its ability to disrupt the cytoskeleton
probably plays an important part. Colchicine may have
anti-inflammatory effects in FMF by reorganizing the
actin cytoskeleton and down regulating Mediterranean
fever (MEFV) gene expression. To date, a median dose
of 1–2 mg daily of colchicine remains the mainstay of
FMF treatment, allowing for significant reduction or ab-
sence of acute attacks in more than 90% of cases [3, 4].
Although considered generally safe and effective, daily
colchicine treatment for FMF has some limitations. In-
deed, colchicine has a narrow therapeutic window at
blood levels < 7 ng/mL, but at doses > 10 ng/mL, it has
serious toxic effects and can lead to potentially fatal out-
comes. This peculiarity is also associated with digestive in-
tolerance, which limits the possibility of increasing the
daily dose to obtain full therapeutic effect in patients with
the most severe (inflammatory) phenotypes. In daily prac-
tice, although colchicine remains an inexpensive and
effective means to control FMF inflammation, 5 to 10% of
patients will not be able to achieve complete response,
which raises the possibility of new therapeutic approaches
such as interleukin 1 (IL-1)-targeting drugs [5–7].
Considering the very high cost of these treatments for
FMF, we aimed to survey when and how adult and
paediatric physicians, consider resistance to colchicine in
patients with FMF and to report how they handle this
situation in their practice.
Patients and methods
Patients and setting
We retrospectively reviewed charts of patients identified
through reference centres and networks of inflammatory-
disease expert physicians. Electronic mailing lists of French
paediatric and adult rheumatologist societies were used to
request medical histories of FMF patients considered resist-
ant to colchicine treatment. We asked physicians to report
patients with a clinical diagnosis of FMF and at least one
pathogenic MEFV mutation whom they considered resist-
ant to colchicine. A dedicated questionnaire was used to
collect data on demographics (age, sex, ethnic origin),
MEFV mutation type, age at first symptoms and at diagno-
sis, description of clinical symptoms before and under col-
chicine treatment, biological inflammatory markers tested
during and between attack periods before and during col-
chicine treatment, associated inflammatory diseases, toler-
ance to treatment, dose adjustments, and evaluation of
adherence to treatment. Disease severity was assessed by
the Tel Hashomer criteria [8]. Finally, we analysed the rea-
sons for physicians considering their patients resistant to
treatment and collected the alternative attitudes and treat-
ments used. We excluded patients with concomitant dis-
eases and manifestations that might mimic FMF, such as
spondyloarthropathies or Crohn’s disease, to avoid confu-
sion in evaluating disease severity.
Statistical analysis
Because we had both paediatric and adult care setting
populations, we first divided the patients into these two
subgroups, with the paediatric care population ranging
in age from 0 to 21 years. We chose this age limit be-
cause several patients were still seeing paediatricians
from age 18 to 21 years. General statistics are reported
as mean ± SD. All descriptive results are given with 95%
confidence intervals (95% CIs). Analyses involved the
chi-square test for categorical variables and t-test for
continuous variables. Microsoft Excel vXI was used for
analysis. P < 0.05 was considered statistically significant.
Results
Study patients
We recruited 51 patients with a clinical diagnosis of
FMF from nine centres, in which four were paediatric
departments. Mean age was 34 ± 23.1 years (range 4.7–
86.3), with 23 males (45%); 23 patients (45%) under
21 years old were in paediatric care setting, in whom 3
between 18 and 21 years old. Thirty (59%) were Sephar-
dic Jews, seven (14%) were from Turkey or Armenia, ten
(20%) were from North Africa, two (4%) were from
Lebanon and two (4%) were of mixed ethnic back-
ground. The mean age at disease onset was 7.8 ± 8.7 years
(range 1 month to 40 years); 17 (33%) had disease on-
set ≤ 2 years. All patients with available data (n = 47/51,
93%) carried pathogenic mutations in exon 10 of MEFV
except one girl and a woman with a complex allele
including MEFV deletion. (Table 1).
Frequency and duration of attacks before and after
colchicine treatment
We had data for 36 patients (72%) before colchicine
treatment; 14 (50%) patients in adult care setting (group
I), 22 (96%) patients in pediatric care setting (group II),
(Table 1). The frequency of attacks was significantly
higher in patients of group II than in those of group
I (p = 0.019). The mean duration of attacks in group
II was 50 h (range 12–84), which was significantly
lower than in group I: 67 h (range 36–96; p = 0.025).
Under colchicine treatment, for 27 (53%) patients, the
number of attacks was > 1/month (15 (65%) in group
II vs. 12 (43%) in group I; p = 0.27). These data were
unavailable for 28% of patients (4% in group II vs.
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47% in group I). The mean duration of attacks under
colchicine treatment was 55 h (range 12–120): 50.5 h
(range 24–120) in group II vs. 60 h (range 11–96) in
group I (p = 0.29).
Severity of attacks before and during colchicine treatment
We had data before colchicine treatment for 22 (43%) pa-
tients for subjective evaluation, because the Tel Hashomer
criteria include the response to colchicine. For all patients,
the attack severity was > 4/10 and for 13 (59%), it was > 7/
10. During colchicine treatment, all 51 patients were classi-
fied by disease severity: disease was severe for 41% (n = 21),
intermediate for 35% (n = 18), and mild for 23% (n = 12).
Clinical features before and during colchicine treatment
Before Colchicine treatment, 44 patients (83%) had fever
during attack periods; these data were unavailable for 3
patients in group I (10%). Overall, 33 patients (73%) had
abdominal pain: 91% in group II versus 57% in group I
(p = 0.009). During Colchicine treatment, 10 (22%) of pa-
tients had myalgia during attack periods, 2 (8%) in group
I vs 8 (36%) in group II, (p = 0.21). Overall symptoms
during attacks before and under colchicine treatment
are detailed in Tables 2 and 3.
Treatment responses and adherence
The mean delay from the first attacks to colchicine
treatment was 8.7 ± 12.9 years (range 0–57): 2.4 ±
2.6 years (range 0–9.8) for group II versus 15 ± 15.9 years
(range 0–57) for group I (p = 0.001). The mean maximal
dose of colchicine given was 2.1 ± 0.7 for group I versus
1.8 ± 0.5 mg (equivalent 0.1 ± 0.01 mg/kg) for group II
(p = 0.006). In all, 30% of group I patients had a dose >
2 mg, with a maximal dose of 3 mg.
A total of 17 patients (32%) had digestive intolerance
[nine of group II (39%) and 14 of group I (27%)], with
diarrhoea as a major symptom. One patient had severe
muscle toxicity, not related to colchicine toxicity. Adher-
ence to colchicine treatment was accurately evaluated in
42 patients (82%): 73% of group I versus 96% of group II
(p = 0.03). Overall, 40% of patients (17/42) declared be-
ing fully adherent: 48% of group II versus 22% of group I
patients (p = 0.08). Among these 42 patients, only three
(7%) had problem of intolerance to Colchicine.
Table 1 Clinical and demographic characteristics of 51 patients








Age at diagnosis (years) 7.8 ± 8.7 12.2 ± 9.6 2.7 ± 2.8 0.001
Sex 0.166
Male 23 (45%) 10 (36%) 13 (57%)
Female 28 (55%) 18 (64%) 10 (43%)
MEFV mutation 0.235
M694V/M694V 27 (51%) 13 (43%) 14 (61%)
M694V/M694I 7 (13%) 4 (13%) 3 (13%)
M694I/M694I 1 (2%) 0 (0%) 1 (4%)
M680I/M680I 1 (2%) 0 (0%) 1 (4%)
M694V/V726A 1 (2%) 1 (3%) 0 (0%)
M694V/I591T 1 (2%) 1 (3%) 0 (0%)
M694V/E148Q 1 (2%) 1 (3%) 0 (0%)
M726V/M680V 1 (2%) 1 (3%) 0 (0%)
M694V/TRAPS polymorph. 1 (2%) 0 (0%) 1 (4%)
E148Q/I692del/V726A 1 (2%) 0 (0%) 1 (4%)
M694V/- 4 (8%) 1 (3%) 3 (13%)
M694I/- 1 (2%) 1 (3%) 0 (0%)
NA 4 (7.5%) 4 (13%) 0 (0%)
Frequency of attacks 0.019
> 1/2 weeks 13 (26%) 5 (18%) 8 (35%)
> 1/month 17 (33%) 7 (25%) 10 (44%)
> 1/3 months, <1/month 3 (6%) 1 (4%) 2 (9%)
< 1/3 months, >3/year 2 (4%) 1 (4%) 1 (4%)
< 3/year 1 (2%) 0 (0%) 1 (4%)
NA 15 (29%) 14 (50%) 1 (4%)
Duration of attacks (hr) 57 ± 22.4 67 ± 17 50 ± 24 0.025
NA 17 (33%) 13 (46%) 4 (17%)
Delay to treatment (years) 8.7 ± 12.9 15 ± 15.9 2.4 ± 2.6 <0.001
Total 51 28 (55%) 23 (45%)
Data are n (%) or mean ± SD
aGroup I: Adult care setting
bGroup II: Pediatric care setting
Table 2 Patient’s clinical symptoms before colchicine therapy





Data available 45 (88%) 22 (79%) 23 (100%)
Fever 44 (83%) 21 (70%) 23 (100%) 0.3
Abdominal pain 33 (73%) 20 (91%) 13 (57%) 0.009
Arthralgia 21 (41%) 11 (39%) 10 (44%) 0.494
Asthenia 2 (4%) 1 (4%) 1 (5%) 0.974
Myalgia 8 (18%) 2 (9%) 6 (26%) 0.136
Thoracic pain 10 (22%) 6 (27%) 4 (17%) 0.4
Diarrhoea 2 (4%) 1 (5%) 1 (4%) 0.974
Amyloidosis 1 (2%) 1 (5%) 0 (0%) 0.301
Skin rash 15 (33%) 8 (36%) 7 (30%) 0.673
Arthritis 6 (13%) 4 (18%) 2 (9%) 0.349
Peritonitis 8 (18%) 2 (9%) 6 (26%) 0.14
Vomiting 2 (4%) 1 (5%) 1 (4%) 0.974
Headache 3 (7%) 0 (0%) 3 (13%) 0.08
¥chi square test
aGroup I: Adult care setting
bGroup II: Pediatric care setting
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Inflammatory markers under colchicine treatment
C-reactive protein (CRP) and serum amyloid A protein
(SAA) levels during attacks were evaluated in 30 (60%)
and 35 patients (69%): mean values were 80 ± 68 and
327 ± 304 mg/L, respectively. Similarly, CRP and SAA
levels between attacks were evaluated in 47 (92%) and
35 patients (69%): mean values were 34 ± 44 and 114 ±
202 mg/L, respectively. Levels did not differ between
group I and group II populations (Fig. 1). Mean erythro-
cyte sedimentation rate between attacks was 34 ± 25 mg/
L and was available for 28 patients (57%; 83% of group
II vs. 32% of group I). Proteinuria between attacks was
evaluated in 33 patients (66%), with mean value < 0.1 g/L
in group II versus 0.7 g/L in group I, seven patients
known to have amyloidosis.
Determination of inadequate response to colchicine
(resistance)
Frequency of attacks
Overall, 38% of patients kept a diary of their crises [70%
of group II vs 13% of group I (p < 0.01)]; 42% were con-
sidered resistant to colchicine because of > 6 attacks/year
[65% of group II vs 23% of group I (p = 0.08)].
Amyloidosis and renal failure
In group I, 22% patients were considered resistant be-
cause of renal amyloidosis under colchicine treatment
(p = 0.02), and 20% because of renal failure, which was a
contraindication to increase the dose to the optimum
(p = 0.02) (Table 4).
Other reasons
In all, 23% of patients had other reasons to be consid-
ered resistant to colchicine treatment: 50% had chronic
arthralgia (three children <18 years in group II and three
patients in group I).
All results are summarized in Table 4
Concomitant and surrogate treatments
Overall, 60% of patients (70% of group II versus 53%
of group I) used concomitant treatments to overcome
FMF symptoms: non-steroidal anti-inflammatory drugs
Table 3 Patient’s clinical symptoms under colchicine therapy





Data available 46 (90%) 24 (86%) 22 (96%)
Fever 40 (87%) 20 (82%) 20 (91%) 0.446
Abdominal pain 37 (80%) 19 (79%) 18 (82%) 0.821
Arthralgia 21 (46%) 11 (46%) 10 (46%) 0.979
Asthenia 13 (28%) 5 (21%) 8 (36%) 0.243
Myalgia 10 (22%) 2 (8%) 8 (36%) 0.021
Thoracic pain 9 (20%) 4 (17%) 5 (23%) 0.605
Diarrhoea 9 (20%) 2 (8%) 7 (32%) 0.045
Amyloidosis 9 (20%) 9 (38%) 0 (0%) 0.001
Skin rash 8 (17%) 2 (8%) 6 (27%) 0.090
Arthritis 7 (15%) 5 (21%) 2 (9%) 0.268
Peritonitis 6 (13%) 3 (13%) 3 (14%) 0.909
Vomiting 5 (11%) 4 (17%) 1 (5%) 0.187
Headache 5 (11%) 1 (4%) 4 (18%) 0.127
¥chi square test
aGroup I: Adult care setting
bGroup II: Pediatric care setting
Fig. 1 C-reactive protein (CRP) level (mg/L) and serum amyloid A
(SAA) (mg/L) levels before and under colchicine treatment.
Horizontal lines are means; outer box edges are SD and whiskers are
95% confidence intervals. *Group I: Adult care setting, **Group II:
Pediatric care setting










> 6/year 42% 23% 65% < 0.08
> 4/6 months 26% 30% 22% ns
Biological inflammation 45% 47% 44% ns
Intolerance to treatment 19% 16% 22% ns
Amyloidosis 22% 0% 0.02
Renal failure 20% 0% 0.02
Other reasons 23% 18% 26% ns
¥By chi-square test
*Group I: Adult care setting
**Group II: Pediatric care setting
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(NSAIDs), steroids, or analgesics. Colchicine was still pre-
scribed for 85% of patients, and 62% of these were treated
receiving IL-1–targeted drugs (61% in group II vs. 63% in
group I). IL-1–targeted drugs were anakinra (79%) or
canakinumab (19%), prescribed as continuous treatment
for 83% of patients.
Discussion
To our knowledge, this is the first study evaluating unre-
sponsiveness to colchicine treatment and physicians’ assess-
ment of it in a cohort of both adult and paediatric care
patients with FMF living in a western European country.
Resistance to colchicine is rare and mostly observed in se-
vereMEFV genotypes. Almost two-thirds of our 51 patients
had homozygous M694 MEFV gene mutations. Less than
half of evaluable patients declared full adherence to colchi-
cine treatment, which was greater for children than adults.
Physician’s reasons for considering colchicine resistance
included > 6 attacks/year, > 4 attacks in the last 6 months,
and persistent inflammation. IL-1–targeting drugs repre-
sented the only alternative treatments in addition to daily
colchicine. The main reasons for assessing resistance were
severe clinical symptoms, persistent subclinical inflamma-
tion, and secondary amyloidosis. Low adherence to colchi-
cine treatment is a key component of resistance, requiring
appropriate patient education.
Renal failure is not a cause for resistance strictly speaking;
nevertheless, renal failure impairs the possibility to increase
the dose of colchicine. This is why we have considered it as
a form of resistance with a cause. The cause of amyloidosis
may be multifactorial, and not only related to non adher-
ence or intolerance, but also due to true resistance or add-
itional genetic and environmental factors.
The study was performed within a network of expert
tertiary centres, which represents a major strength of the
optimal care available in our country. The study gives im-
portant data because resistance to colchicine is responsible
for increased disease-related morbidity, mortality and poor
quality of life with FMF [9, 10]. Thus, resistant patients
seem to be good candidates for biologic treatment (i.e.,
anti-IL-1 treatments). Nevertheless, none of these drugs are
being approved, and increasing their use may greatly
increase the overall cost of care for FMF [6, 7, 11].
Our study confirmed two important points: first, insuffi-
cient response to colchicine treatment is rare (about 10% of
all patients seen in our centres); second, insufficient re-
sponse affects mostly patients with the most severe disease
pattern and pathogenic MEFV mutations [10]. FMF sever-
ity in our patients was reflected by a high number of attacks
per year, a high frequency of musculoskeletal involvement,
and secondary amyloidosis. Of note, we excluded patients
with amyloidosis as a presenting feature of FMF before
colchicine treatment. Chronic musculoskeletal symptoms
were another cause, well known to be generally benign and
overcome with NSAIDs, but in a few cases, they can cause
absenteeism from school or work. Some of these patients
may show increased risk of developing secondary spondy-
loarthropathies, which was an exclusion criterion in our
study [12]. Secondary amyloidosis appearing during the
course of FMF was also a leading cause of resistance to
colchicine, exclusively observed in the adult population.
Physician’s assessment of resistance to colchicine treatment
was in accordance with the definition of the French Israeli
consortium, “six or more typical attacks in a year or three
in 4–6 months with an elevated acute phase response be-
tween attacks,” and with the new EULAR recommenda-
tions, at least 1 attack/month in a 6-month period with full
adherence to colchicine treatment [4, 13]. Another finding
is that a number of patients, especially children, received
doses of colchicine higher than that recommended and ex-
perienced digestive symptoms of intolerance, which could
be considered not strictly synonymous with resistance to
treatment. Colchicine is mainly absorbed from jejunal and
ileal mucosa and mainly eliminated via biliary excretion
(10–20% renal excretion). Anorexia, nausea, diarrhoea, and
increased liver enzyme activity are the most common signs
of intolerance; these can be overcome in part by twice-daily
divided doses, but there are also probably individual differ-
ences regarding this issue [14]. Of note, severe fatal intoxi-
cations have been reported with concomitant use of
clarithromycin and other drugs using the same cytochrome
P450 metabolic pathways, which can lead to colchicine ac-
cumulation apart from situations of overdose. Alimentary
factors may also be involved, and the concomitant intake of
grapefruit juice or plants (St. John’s wort) may also increase
colchicine toxicity. Another major issue raised by our study
and others is the very low full adherence to daily colchicine
treatment (40%), even lower than previously reported
(60%), which can only be partially explained by digestive in-
tolerance [14]. Indeed, paediatric patients received higher
doses than adults and had more side effects but were more
fully adherent than adults (48% vs 22%). The international
recommendations distinguish low adherence from resist-
ance to colchicine treatment [4, 13], but the practical way
to improve the management of this critical issue needs to
be determined. New findings have shown that psychological
“stress” is sensed by the innate immune system in the brain
via the ATP/P2X7R-NLRP3 inflammasome cascade; revers-
ing the activation of this pathway in mice blocked the re-
lease of IL-1β (1–3 days after infusion) and produced
antidepressant and anxiolytic behavioural effects in non-
stressed mice [15]. Many of our patients could benefit from
biological treatments that were exclusively anti-IL-1 drugs.
Although not within the scope of this study, these treat-
ments gave good response for FMF-related musculoskeletal
symptoms and secondary amyloidosis. According to inter-
national recommendations, all patients were prescribed
daily colchicine, when still possible.
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Conclusion
Despite our retrospective study with some missing data
and possible recall bias, it brings important insights into
factors affecting inadequate response to colchicine treat-
ment for FMF. Besides the severity of the disease itself,
low adherence to treatment is of major importance and
remains a challenge for all physicians. Searching for
possible causes of digestive intolerance and promoting
patient education to reinforce stress control and encour-
age adherence to treatment may decrease the need for
expensive alternative treatments.
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